Atossa Therapeutics (NASDAQ:ATOS – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $6.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 337.96% from the company’s current price.
Several other equities analysts have also weighed in on ATOS. StockNews.com raised Atossa Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, October 25th. Ascendiant Capital Markets increased their price objective on Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a report on Wednesday, September 11th.
Check Out Our Latest Analysis on ATOS
Atossa Therapeutics Stock Down 2.8 %
Atossa Therapeutics (NASDAQ:ATOS – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. As a group, equities research analysts anticipate that Atossa Therapeutics will post -0.22 EPS for the current fiscal year.
Hedge Funds Weigh In On Atossa Therapeutics
Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its holdings in shares of Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after acquiring an additional 399,041 shares during the period. Cetera Advisors LLC bought a new position in shares of Atossa Therapeutics in the first quarter worth $72,000. Virtu Financial LLC bought a new position in shares of Atossa Therapeutics in the first quarter worth $151,000. Rhumbline Advisers bought a new position in shares of Atossa Therapeutics in the second quarter worth $161,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Atossa Therapeutics by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after acquiring an additional 78,269 shares during the period. 12.74% of the stock is owned by institutional investors.
About Atossa Therapeutics
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Further Reading
- Five stocks we like better than Atossa Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Utilities Stocks Explained – How and Why to Invest in Utilities
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.